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Abstract
Limited evidence is available regarding antiretroviral (ARV) safety
for uninfected infants exposed to these drugs in utero. Our objective
was to determine if ARV administered to pregnant women is associ-
ated with decreasing umbilical arterial pH and base excess in uninfect-
ed infants. A prospective study was conducted on 57 neonates divided
into three groups: ZDV group, born to mothers taking zidovudine (N
= 20), triple therapy (TT) group, born to mothers taking zidovudine +
lamivudine + nelfinavir (N = 25), and control group (N = 12), born to
uninfected mothers. Umbilical cord blood was used to determine
umbilical artery gases. A test was performed to calculate the sample
by comparing means by the unpaired one-tailed t-test, with α = 0.05
and ß = 20%, indicating the need for a sample of 18 newborn infants
for the study groups to detect differences higher than 20%. The control
and ARV groups were similar in gestational age, birth weight, and
Apgar scores. Values of pH, pCO2, bicarbonate, and base excess in
cord arterial blood obtained at delivery from the newborns exposed to
TT were 7.23, 43.2 mmHg, 19.5 mEq/L, and -8.5 nmol/L, respective-
ly, with no significant difference compared to the control and ZDV
groups. We conclude that intrauterine exposure to ARV is not associ-
ated with a pathological decrease in umbilical arterial pH or base
excess. While our data are reassuring, follow-up is still limited and
needs to be continued into adulthood because of the possible potential
for adverse effects of triple antiretroviral agents.
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Pregnant women are increasingly being
treated with multiple antiretroviral (ARV)
drugs to improve maternal health and to
reduce the risk of vertical transmission of
HIV infection. Nucleoside reverse transcrip-
tase inhibitors cross the placenta and reach a
variable newborn/mother drug ratio, i.e., ap-
proximately 0.85 for zidovudine (ZDV) and
1.0 for lamivudine. Although this maternal-
fetal transfer is beneficial for the prevention
of the vertical transmission of HIV-1, it may
expose the infant to the risk of adverse ef-
fects (1,2).
Although this subject is controversial,
Brazilian Journal of Medical and Biological Research (2007) 40: 957-961
ISSN 0100-879X Short Communication
958
Braz J Med Biol Res 40(7) 2007
P. El-Beitune et al.
www.bjournal.com.br
search Ethics Committee of the Institution,
Hospital das Clínicas da Faculdade de Medi-
cina de Ribeirão Preto, Universidade de São
Paulo, Ribeirão Preto, SP, Brazil, and writ-
ten informed consent to participate was ob-
tained from each subject.
To evaluate factors potentially associ-
ated with umbilical arterial blood pH abnor-
malities from birth, we adjusted analyses for
gestational age at birth, mode of delivery,
alcohol use, illicit drug use during gestation,
and tobacco use. Pregnant women with hy-
pertension, diabetes mellitus, seizures, still-
birth, or macrosomia in their previous preg-
nancies, and pathological fetal heart rate
tracings and women who did not comply
with the use of ARV drugs or used them
irregularly and also infants presenting con-
genital infections or malformations were
excluded. Biochemical evaluation was not
concluded in two ZDV group and three TT
group infants due to concomitance of exclu-
sion criteria.
Blood samples were drawn from a dou-
bly clamped cord segment into 3-mL plastic
syringes flushed with a 1000-U/mL heparin
solution. Measurements were performed
within 15 min after delivery. Arterial blood
gases were determined by an automated
method using the Rapid Lab-860 system of
Bayer (Tarrytown, NY, USA).
Since we expected that the use of ARV
drugs during pregnancy would elevate pCO2
and reduce pH and base excess compared to
controls (12 newborn infants), a test was
performed to calculate the sample by com-
paring means by the unpaired one-tailed t-
test, with α = 0.05 and ß = 20%, indicating
the need for a sample of 18 newborn infants
for the study groups, considering the interest
in detecting pathologic data of pCO2 of about
65 mmHg, pH 7.10, and base excess higher
than 12 nmol/L. The GraphPad StatMate
1.01 software was used for these calcula-
tions.
The variability of the acid-base balance
in cord arterial blood was calculated on the
prophylaxis with ZDV has been implicated
in changes in the neurological and cognitive
development of children exposed to HIV but
not infected with the virus (3). Limited evi-
dence is available regarding ARV safety for
uninfected infants exposed to these drugs in
utero. Most of the studies that have ad-
dressed the intrauterine well-being of these
infants have determined a perinatal progno-
sis based on Apgar scores and fetal and
neonatal death (4,5). In addition, umbilical
artery blood pH and gas analysis are increas-
ingly recognized as the most reliable indica-
tors of fetal oxygenation and acid-base con-
dition at birth (6,7). Therefore, our objective
was to evaluate the effect of two different
intrauterine exposures, ZDV alone or triple
antiretroviral treatment with ZDV, lamivu-
dine (3TC) and nelfinavir (NFV) on the
umbilical artery blood pH and gas analysis
at birth in HIV-exposed children.
We carried out a prospective study on 45
HIV-1-infected women and 12 uninfected
pregnant women with singleton gestations.
Only HIV-infected patients who had not
been treated previously with ARV were se-
lected for the study. The HIV-1-infected
women were divided into two groups named
ZDV group and triple treatment (TT) group.
The ZDV group consisted of 20 pregnant
women who fulfilled the requirements for
the prophylactic use of ZDV (CD4 >500
cells/mm3 and viral load <1000 copies/mL).
The TT group consisted of 25 pregnant
women with a clinical and laboratory indica-
tion (CD4 <500 cells/mm3) for triple anti-
retroviral treatment (ZDV + 3TC + NFV)
according to the criteria established by the
Perinatal HIV Guidelines Working Group
Members regarding ARV treatment of preg-
nant women (2).
The ARV agents recommended since the
14th week of pregnancy were ZDV, 300 mg/
dose, twice a day for the ZDV group, and
300 mg ZDV, 150 mg 3TC, and 1250 mg
NFV in two daily doses for the TT group.
The present study was approved by the Re-
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basis of the median and interquartile varia-
tion (1st and 3rd quartiles, respectively).
The nonparametric chi-square, Mann-Whit-
ney and Kruskal-Wallis tests were used, with
the level of significance set at P < 0.05. All
analyses were performed using the SPSS
10.0 software.
Median maternal age was 22.5 years,
with an interquartile (IQ) variation of 6 years
in the control group, 24 years (IQ of 7 years)
in the ZDV group, and 27 years (IQ of 6
years) in the TT group, with no significant
difference in these variables between groups
(Kruskal-Wallis test, P = 0.13). With respect
to race (white and non-white), 83, 50, and
68% of the women in the control, ZDV and
TT groups were white, respectively (chi-
square test, P = 0.14). Smoking habits also
were not significantly different, with 91, 60,
and 80% of the subjects in the control, ZDV
and TT groups being non-smokers, respec-
tively (chi-square test, P = 0.10). Alcohol
drinking also did not differ significantly be-
tween groups (chi-square test, P = 0.14).
Median gestational age at delivery was
39 weeks for the control group, 38.1 weeks
for the ZDV group and 38.5 weeks for the
TT group (Kruskal-Wallis test, P = 0.57).
Median infant weight was 3250, 3080, and
3100 g for the control, ZDV and TT groups,
respectively (Kruskal-Wallis test, P = 0.447).
Analysis of these variables, of the Apgar
score and of adequacy of anthropometric
classification did not indicate any signifi-
cant differences among the newborns of the
various groups (chi-square test, P = 0.59).
Cesarean section was performed in 16.7,
45.0, and 36.0% of the control, ZDV and TT
groups, respectively (chi-square test, P =
0.26).
Table 1 presents the values of pH, pCO2,
bicarbonate, and base excess in cord arterial
blood from the newborn at the time of deliv-
ery. No significant differences were observed
between cases and controls. Even though the
results of the present series support the safety
of the use of two schemes of ARV therapy
during pregnancy, i.e., ZDV prophylaxis and
combination of ARV agents, a limitation
exists, based on the power of the study re-
ported here to detect an effect of lower mag-
nitude among groups.
In the present patient series, no differ-
ence in gestational age or in newborn birth
weight was observed, nor did the 1st and 5th
min Apgar scores differ between the three
groups studied. These data are similar to
those obtained in other studies and meta-
analyses which demonstrated that the gesta-
tional and immediate neonatal prognosis were
not impaired among pregnant women exclu-
sively taking ZDV or taking drug combina-
tions containing or not protease inhibitors
during the prenatal period (8-11).
Despite the vast literature available about
the potentiation of the adverse effects of
ARV in adults (2,11,12), there are no pro-
spective studies emphasizing the effect of
Table 1. Newborn pH, pCO2, bicarbonate (HCO3), and base excess (BE) in cord arterial blood at the time of
delivery.
Group pH  pCO2 (mmHg)  HCO3 (mEq/L) BE (nmol/L)
Control (N = 12) 7.25 (7.20-7.28) 40.0 (31.9-48.9) 17.7 (15.1-18.9) -10.3 (-10.9 to -6.9)
ZDV (N = 18) 7.22 (7.14-7.26) 47.3 (41.9-51.9) 18.3 (16.9-20.3) -8.8 (-11.6 to -6.9)
TT (N = 22) 7.23 (7.15-7.30) 43.2 (40.6-46.6) 19.5 (17.3-20.7) -8.5 (-12.6 to -5.8)
P 0.24 0.11 0.13 0.72
Data are reported as medians and 1st and 3rd quartiles. Control = uninfected pregnant women with no
antiretroviral agents; ZDV = 300 mg zidovudine twice a day; TT = triple therapy with 300 mg zidovudine + 150
mg lamivudine + 1250 mg nelfinavir twice a day. There were no statistically significant differences between
groups (Kruskal-Wallis test).
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maternal ARV agent use on acid-base bal-
ance at delivery of the neonate, which objec-
tively reflects the placental respiratory and
metabolic conditions of the infant at birth,
using these data as a basis for the clinical
results observed (7,13,14).
The pH value observed was 7.25 for the
control group, with no significant differ-
ences compared to the cases. Similarly, pla-
cental respiratory and metabolic function
did not differ between groups. Our clinical
data agree with those reported for children
exposed to HIV but not infected followed up
in the multicenter PACTG 076 study for a
mean period of 4.2 years (range: 3.2-5.6
years), in which no difference in neurologi-
cal, cognitive or behavioral development
was observed compared to the control group
(15). In addition, in a meta-analysis con-
ducted on a total of 2123 HIV-infected preg-
nant women who had received ARV therapy
during the prenatal period (ZDV alone in
1590, combined therapy without protease
inhibitors in 396, and combined therapy with
protease inhibitors in 137) and on 1143
women who did not receive ARV therapy
during pregnancy, the use of ARV medica-
tions was also not associated with low Apgar
scores or fetal death compared to untreated
women or women taking ZDV alone (9).
In conclusion, no association was ob-
served between the use of ARV drugs and
pathological gas changes in umbilical cord
arterial blood, with similar data being de-
tected for the three groups regarding pH,
pCO2, base deficit, and bicarbonate. Our
results suggest safety of the use of ARV
drugs during pregnancy regarding fetal oxy-
genation and acid-base condition at birth.
On the other hand, the “gold standard” is to
conduct follow-up of children with intra-
uterine ARV drug exposure into adulthood
because of the possible potential for adverse
metabolic and hematological effects of a
combined scheme with protease inhibitors
(16,17).
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